{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["5(9)"],"submitter":["Buchan SA"],"pubmed_abstract":["<h4>Importance</h4>The incidence of SARS-CoV-2 infection, including among individuals who have received 2 doses of COVID-19 vaccine, increased substantially following the emergence of the Omicron variant in Ontario, Canada. Understanding the estimated effectiveness of 2 or 3 doses of COVID-19 vaccine against outcomes associated with Omicron and Delta infections may aid decision-making at the individual and population levels.<h4>Objective</h4>To estimate vaccine effectiveness (VE) against symptomatic infections due to the Omicron and Delta variants and severe outcomes (hospitalization or death) associated with these infections.<h4>Design, setting, and participants</h4>This test-negative case-control study used linked provincial databases for SARS-CoV-2 laboratory testing, reportable disease"],"journal":["JAMA network open"],"pagination":["e2232760"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9500552"],"repository":["biostudies-literature"],"pubmed_title":["Estimated Effectiveness of COVID-19 Vaccines Against Omicron or Delta Symptomatic Infection and Severe Outcomes."],"pmcid":["PMC9500552"],"pubmed_authors":["Gubbay JB","Sundaram ME","Wilson K","Chung H","Fell DB","Schwartz KL","Tadrous M","Nasreen S","Wilson SE","Buchan SA","Kwong JC","Austin PC","Brown KA"],"additional_accession":[]},"is_claimable":false,"name":"Estimated Effectiveness of COVID-19 Vaccines Against Omicron or Delta Symptomatic Infection and Severe Outcomes.","description":"<h4>Importance</h4>The incidence of SARS-CoV-2 infection, including among individuals who have received 2 doses of COVID-19 vaccine, increased substantially following the emergence of the Omicron variant in Ontario, Canada. Understanding the estimated effectiveness of 2 or 3 doses of COVID-19 vaccine against outcomes associated with Omicron and Delta infections may aid decision-making at the individual and population levels.<h4>Objective</h4>To estimate vaccine effectiveness (VE) against symptomatic infections due to the Omicron and Delta variants and severe outcomes (hospitalization or death) associated with these infections.<h4>Design, setting, and participants</h4>This test-negative case-control study used linked provincial databases for SARS-CoV-2 laboratory testing, reportable disease","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Sep","modification":"2026-06-03T13:18:26.331Z","creation":"2025-04-07T10:41:00.025Z"},"accession":"S-EPMC9500552","cross_references":{"pubmed":["36136332"],"doi":["10.1001/jamanetworkopen.2022.32760"]}}